EN
Home/Answers/Switching medicines
ALLAll countries Medicines

How do you switch between tirzepatide and semaglutide?

What we checked13 sources, each one opened and linked to the sentence it supportsLast checked Nov 15, 2026 · Next review due Nov 15, 2027 · How we write
The short answer

No label we read gives a dose that converts tirzepatide (Mounjaro, Zepbound) into semaglutide (Ozempic, Wegovy), or back. The US, EU, UK, Canadian and Australian labels say not to use the two together and give only their own starting doses: 2.5 mg a week for tirzepatide, 0.25 mg for Wegovy. A prescriber sets the new dose and timing.

Is there a dose conversion between tirzepatide and semaglutide?

No. None of the US, EU, UK, Canadian or Australian labels we read converts a tirzepatide dose into a semaglutide dose, or the reverse.1,2,3,4,7,9,10

Each label gives only its own starting dose. Tirzepatide starts at 2.5 mg once a week for 4 weeks. The US Zepbound label says this dose is for starting treatment and is not a maintenance dose.1,4,5,7,9 Wegovy (semaglutide) starts at 0.25 mg a week. The EU label raises it over 16 weeks to make stomach symptoms less likely.2,3,6,8

The labels don’t say whether someone coming from the other medicine starts at the bottom or higher. A UK pharmacy-journal training article says “there is no validated dose equivalence between the two agents” and suggests restarting semaglutide at 0.25 mg. Its author is a clinical trainer for Eli Lilly.12

The only switch the labels describe stays within semaglutide. The US Wegovy label moves people from the 2.4 mg injection to the 25 mg tablet one week after the last injection.2 The EU label says the effect of switching between tablet and injection “cannot easily be predicted”.3

Can you overlap them, and how long is the gap?

Not at the same time. The Zepbound and Wegovy labels say using either with another GLP‑1 medicine is not recommended, and none we read sets a waiting gap.1,2,7,8,10

The EU Wegovy label gives the reason. The combination has not been tested, and a higher risk of overdose side effects “is considered likely”.3

Both medicines stay in the body after the last dose. Half-life means the time it takes for half the medicine to leave your blood. Semaglutide’s is about 1 week, and the US Wegovy label says it stays in the blood for 5 to 7 weeks after the last 2.4 mg dose.2 Tirzepatide’s is about 5 days.1

A delay between the two brings in the missed-dose rules. After 2 or more missed Wegovy injections in a row, the US label restarts the dose climb lower; the EU label says a lower restart should be considered.2,3 A missed Zepbound dose can be taken within 4 days; after that, it is skipped.1

Will side effects or results change after a switch?

They can. Stomach side effects are most common while a dose is rising, and each label starts its medicine with a slow climb through the doses.1,3,5

In the US Zepbound weight trials, 25 to 29 in 100 people on 5 to 15 mg had nausea, against 8 in 100 on a dummy injection (placebo). Most nausea, vomiting and diarrhoea happened while the dose rose, then eased.1 On Wegovy 2.4 mg, 44 in 100 had nausea, against 16 in 100 on placebo.2 Fluid lost through vomiting or diarrhoea has led to kidney injury.1

The one head-to-head trial, SURMOUNT-5, gave 751 adults with obesity and no diabetes one medicine or the other from the start. After 72 weeks, weight fell 20.2% on tirzepatide 10 or 15 mg and 13.7% on semaglutide 1.7 or 2.4 mg. Nobody switched, and Eli Lilly paid for the trial.11

What do people report after switching between tirzepatide and semaglutide?

From public patient forums: 2,282 Reddit threads in r/Zepbound, r/WegovyWeightLoss, r/mounjarouk, r/Mounjaro, r/Semaglutide and r/WegovyUK, read from October 2025 to October 2026. Personal reports, not medical evidence.

What people describe

  • Matches the label Several say the new medicine’s first dose seemed to do little until they reached higher steps. The US Zepbound label calls 2.5 mg a starting dose, not a maintenance dose.1
  • Not studied Results were mixed both ways. Several say semaglutide felt weaker after tirzepatide, while several others did fine on it. Several say tirzepatide restarted their weight loss, and a few did better on semaglutide. We found no trial of switching.
  • Matches the label A few describe new or worse vomiting, reflux or constipation soon after switching, sometimes after starting the new medicine high. The labels say stomach side effects cluster while the dose rises.1,5
  • Matches the label Several say prescribers chose very different starting doses. No label we read gives a conversion between the two.1,2,3,4

Advice people share

  • Matches the label Several advise giving each dose about 4 weeks before judging it. The labels raise doses in steps of at least 4 weeks.1,5
  • Not studied A few say no extra gap is needed and start the new medicine on the next usual injection day; others were told to wait 1 to 5 weeks. We found no study of the gap, and the labels set none.
  • Label says otherwise A few describe starting high with no step-up, or overlapping the two medicines. The labels start tirzepatide at 2.5 mg and Wegovy at 0.25 mg, and say not to use them together.1,2
  • Label says otherwise Several describe making doses a pen or vial wasn’t made for. The US Zepbound label gives each single-dose pen one fixed dose, and each KwikPen 4 doses.1

In your country

No label we read converts doses between the two medicines; brand names, the label we could open and the emergency number differ by country.

Australia

Sold as: Tirzepatide: Mounjaro. Semaglutide injection, weight: Wegovy. Semaglutide injection, diabetes: Ozempic. Semaglutide tablets, weight: none (Wegovy pill treated as not approved). Semaglutide tablets, diabetes: Rybelsus approved; whether supplied not confirmed.

Label: The answer above applies.

Emergency number: 000

Doctors and medicines in Australia

Canada

Sold as: Tirzepatide: Mounjaro, Mounjaro KwikPen, Zepbound. Semaglutide injection, weight: Wegovy. Semaglutide injection, diabetes: Ozempic; Semaglutide Injection (Dr. Reddy’s; shortage reported Jul 2026, lots recalled Aug 2026); Apo-Semaglutide (one lot recalled Aug 2026). Semaglutide tablets, weight: none (no oral Wegovy in Health Canada’s drug database). Semaglutide tablets, diabetes: Rybelsus. Semaglutide approved but not marketed: Sevmia, Poviztra, Plosbrio, Aspen-Semaglutide, Semaglutide Injection (Aspen), Sandoz Semaglutide.

Label: The answer above applies.

Emergency number: 911

Doctors and medicines in Canada

France

Sold as: Tirzepatide: Mounjaro. Semaglutide injection, weight: Wegovy. Semaglutide injection, diabetes: Ozempic. Semaglutide tablets, weight: none (Wegovy pill not sold in France). Semaglutide tablets, diabetes: none found (Rybelsus not in France’s medicines database).

Label: The answer above applies.

Emergency number: 15 or 112

Doctors and medicines in France

Germany

Sold as: Tirzepatide: Mounjaro. Semaglutide injection, weight: Wegovy, including 7.2 mg. Semaglutide injection, diabetes: Ozempic. Semaglutide tablets, weight: Wegovy Tablette. Semaglutide tablets, diabetes: Rybelsus.

Label: The answer above applies.

Emergency number: 112

Doctors and medicines in Germany

India

Sold as: Tirzepatide: Mounjaro, Yurpeak. Semaglutide injection, weight: Wegovy; Poviztra; Noveltreat. Semaglutide injection, diabetes: Ozempic; Obeda (Dr Reddy’s; recalled Jul 2026 over an active-ingredient impurity; on 23 Oct 2026 the company said it planned to relaunch in Nov; resumption not confirmed at 8 Nov 2026; distributors told Reuters it may be discontinued); Sematrinity; GLIPIQ; Semalix (batches recalled Jul 2026); Semanat; Semafull. Semaglutide injection, diabetes and weight: Semaglyn; Mashema; Alterme; Semasize; Obesema; Hepaglide. Semaglutide, diabetes and weight (form not confirmed): Obeda Pro; Obeda Plus (Dr Reddy’s, made by Hetero Labs; in the market from late Jul 2026). Semaglutide injection, use not confirmed: Semanext; Livarise; Sundae. Semaglutide, form and use not confirmed: Samakind; Usema (batches recalled). Semaglutide tablets, weight: not confirmed. Semaglutide tablets, diabetes: Rybelsus; Sembolic; Obeda (tablets not part of the Jul 2026 recall).

Label: We found no public Indian label, so this page relies on the US and EU labels.1,2,3,4

Emergency number: 112

Doctors and medicines in India

Saudi Arabia

Sold as: Tirzepatide: Mounjaro, Mounjaro KwikPen. Semaglutide injection, weight: Wegovy. Semaglutide injection, diabetes: Ozempic; Tasylev; Lugyda; Glucentra. Semaglutide tablets, weight: none (Wegovy pill not registered). Semaglutide tablets, diabetes: Rybelsus.

Label: We found no public Saudi label text to check, so this page relies on the US and EU labels.1,2,3,4

Emergency number: 997 or 911

Doctors and medicines in Saudi Arabia

United Arab Emirates

Sold as: Tirzepatide: Mounjaro. Semaglutide injection, weight: Wegovy. Semaglutide injection, diabetes: Ozempic. Semaglutide tablets, weight: Wegovy pill. Semaglutide tablets, diabetes: Rybelsus.

Label: We found no public UAE label text to check, so this page relies on the US and EU labels.1,2,3,4

Emergency number: 998 for an ambulance, or 999

Doctors and medicines in the UAE

United Kingdom

Sold as: Tirzepatide: Mounjaro. Semaglutide injection, weight: Wegovy, including 7.2 mg. Semaglutide injection, diabetes: Ozempic. Semaglutide tablets, weight: Wegovy tablets (authorised 11 Jun 2026; retail sale not confirmed). Semaglutide tablets, diabetes: Rybelsus.

Label: The answer above applies.

Emergency number: 999

Doctors and medicines in the UK

United States

Sold as: Tirzepatide: Zepbound, Mounjaro. Semaglutide injection, weight: Wegovy, including Wegovy HD 7.2 mg. Semaglutide injection, diabetes: Ozempic. Semaglutide tablets, weight: Wegovy pill. Semaglutide tablets, diabetes: Ozempic tablets; Rybelsus (being discontinued).

Label: The answer above applies.

Emergency number: 911

Doctors and medicines in the US

Get help now: call your local emergency number for severe belly pain or pressure, severe or persistent vomiting or diarrhoea, fainting, breathing problems, or swelling of the face, eyes or tongue.13 Emergency numbers: 911 in the US and Canada, 999 in the UK, 998 or 999 in the UAE, 000 in Australia, 112 in India and Germany, 15 or 112 in France, 997 or 911 in Saudi Arabia.

Contact your prescriber or a doctor right away if nausea, vomiting or diarrhoea keeps going, or if belly pain could be pancreatitis: severe pain that may spread to the back, with or without vomiting.1

Read the full picture

Related questions

Did this answer your question?

Sources

  1. Eli Lilly. Zepbound (tirzepatide) injection: US prescribing information, revised 08/2026. US label. pi.lilly.com
  2. Novo Nordisk. Wegovy (semaglutide) injection and tablets: US prescribing information, revised 06/2026. US label. novo-pi.com
  3. European Medicines Agency. Wegovy (semaglutide): EU summary of product characteristics, sections 4.2 and 4.4. EU label. ema.europa.eu
  4. European Medicines Agency. Mounjaro (tirzepatide): EU summary of product characteristics, section 4.2. EU label. ema.europa.eu
  5. Eli Lilly. Mounjaro KwikPen (tirzepatide): UK summary of product characteristics, sections 4.2 and 4.8. UK label. medicines.org.uk
  6. Novo Nordisk. Wegovy (semaglutide) FlexTouch: UK summary of product characteristics, sections 4.2 and 4.4. UK label. medicines.org.uk
  7. Eli Lilly Canada. Zepbound (tirzepatide injection): Canadian product monograph. Canadian label. pdf.hres.ca
  8. Novo Nordisk Canada. Wegovy (semaglutide injection): Canadian product monograph. Canadian label. pdf.hres.ca
  9. Eli Lilly. Mounjaro (tirzepatide): Australian Product Information, vA14.0, October 2026, section 4.2. Australian label. medsinfo.com.au
  10. Novo Nordisk. Wegovy (semaglutide): Australian Product Information, sections 4.2 and 4.4. Australian label. medsinfo.com.au
  11. Aronne LJ, Horn DB, le Roux CW et al. Tirzepatide as compared with semaglutide for the treatment of obesity (SURMOUNT-5). N Engl J Med 2025. Funded by Eli Lilly. PubMed 40353578
  12. Shahid S. Switching between weight-loss medications. The Pharmaceutical Journal, CPD & Learning, last updated 27 July 2026. The author is a clinical trainer for Eli Lilly. pharmaceutical-journal.com
  13. MedlinePlus (US National Library of Medicine). Recognizing medical emergencies, listing the American College of Emergency Physicians warning signs. Reviewed 8 January 2025. medlineplus.gov

Last checked Nov 15, 2026 · Next review due Nov 15, 2027 · Report an error

How this answer was made. Written by the GLP Guidebook team from the sources above, all checked on Nov 15, 2026. The “What people report” section summarises public patient forum posts we read; it is not medical evidence, and we never pass on advice that goes against the label. We give no dose conversions between medicines, because no label we read gives one. It’s general information, not medical advice. Talk to a doctor, pharmacist or other licensed prescriber before starting, stopping or changing any medicine. In an emergency, call your local emergency number. How we write